Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

Erik H. van Beers, Martin H. van Vliet, Rowan Kuiper, Leonie de Best, Kenneth C. Anderson, Ajai Chari, Sundar Jagannath, Andrzej Jakubowiak, Shaji K Kumar, Joan B. Levy, Daniel Auclair, Sagar Lonial, Donna Reece, Paul Richardson, David S. Siegel, Alexander Keith Stewart, Suzanne Trudel, Ravi Vij, Todd M. Zimmerman, Rafael Fonseca

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: High risk and low risk multiple myeloma patients follow a very different clinical course as reflected in their PFS and OS. To be clinically useful, methodologies used to identify high and low risk disease must be validated in representative independent clinical data and available so that patients can be managed appropriately. A recent analysis has indicated that SKY92 combined with the International Staging System (ISS) identifies patients with different risk disease with high sensitivity. Patients and Methods: Here we computed the performance of eight gene expression based classifiers SKY92, UAMS70, UAMS80, IFM15, Proliferation Index, Centrosome Index, Cancer Testis Antigen and HM19 as well as the combination of SKY92/ISS in an independent cohort of 91 newly diagnosed MM patients. Results: The classifiers identified between 9%-21% of patients as high risk, with hazard ratios (HRs) between 1.9 and 8.2. Conclusion: Among the eight signatures, SKY92 identified the largest proportion of patients (21%) also with the highest HR (8.2). Our analysis also validated the combination SKY92/ISS for identification of three classes; low risk (42%), intermediate risk (37%) and high risk (21%). Between low risk and high risk classes the HR is >10.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - 2017

Fingerprint

Multiple Myeloma
Centrosome
Testicular Neoplasms
Gene Expression
Antigens

Keywords

  • Biomarker
  • Gene expression
  • In vitro diagnostic clinical assay
  • Signature

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. / van Beers, Erik H.; van Vliet, Martin H.; Kuiper, Rowan; de Best, Leonie; Anderson, Kenneth C.; Chari, Ajai; Jagannath, Sundar; Jakubowiak, Andrzej; Kumar, Shaji K; Levy, Joan B.; Auclair, Daniel; Lonial, Sagar; Reece, Donna; Richardson, Paul; Siegel, David S.; Stewart, Alexander Keith; Trudel, Suzanne; Vij, Ravi; Zimmerman, Todd M.; Fonseca, Rafael.

In: Clinical Lymphoma, Myeloma and Leukemia, 2017.

Research output: Contribution to journalArticle

van Beers, EH, van Vliet, MH, Kuiper, R, de Best, L, Anderson, KC, Chari, A, Jagannath, S, Jakubowiak, A, Kumar, SK, Levy, JB, Auclair, D, Lonial, S, Reece, D, Richardson, P, Siegel, DS, Stewart, AK, Trudel, S, Vij, R, Zimmerman, TM & Fonseca, R 2017, 'Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma', Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2017.06.020
van Beers, Erik H. ; van Vliet, Martin H. ; Kuiper, Rowan ; de Best, Leonie ; Anderson, Kenneth C. ; Chari, Ajai ; Jagannath, Sundar ; Jakubowiak, Andrzej ; Kumar, Shaji K ; Levy, Joan B. ; Auclair, Daniel ; Lonial, Sagar ; Reece, Donna ; Richardson, Paul ; Siegel, David S. ; Stewart, Alexander Keith ; Trudel, Suzanne ; Vij, Ravi ; Zimmerman, Todd M. ; Fonseca, Rafael. / Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. In: Clinical Lymphoma, Myeloma and Leukemia. 2017.
@article{936c84df4a1a41b0a9351dbcab10c145,
title = "Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma",
abstract = "Background: High risk and low risk multiple myeloma patients follow a very different clinical course as reflected in their PFS and OS. To be clinically useful, methodologies used to identify high and low risk disease must be validated in representative independent clinical data and available so that patients can be managed appropriately. A recent analysis has indicated that SKY92 combined with the International Staging System (ISS) identifies patients with different risk disease with high sensitivity. Patients and Methods: Here we computed the performance of eight gene expression based classifiers SKY92, UAMS70, UAMS80, IFM15, Proliferation Index, Centrosome Index, Cancer Testis Antigen and HM19 as well as the combination of SKY92/ISS in an independent cohort of 91 newly diagnosed MM patients. Results: The classifiers identified between 9{\%}-21{\%} of patients as high risk, with hazard ratios (HRs) between 1.9 and 8.2. Conclusion: Among the eight signatures, SKY92 identified the largest proportion of patients (21{\%}) also with the highest HR (8.2). Our analysis also validated the combination SKY92/ISS for identification of three classes; low risk (42{\%}), intermediate risk (37{\%}) and high risk (21{\%}). Between low risk and high risk classes the HR is >10.",
keywords = "Biomarker, Gene expression, In vitro diagnostic clinical assay, Signature",
author = "{van Beers}, {Erik H.} and {van Vliet}, {Martin H.} and Rowan Kuiper and {de Best}, Leonie and Anderson, {Kenneth C.} and Ajai Chari and Sundar Jagannath and Andrzej Jakubowiak and Kumar, {Shaji K} and Levy, {Joan B.} and Daniel Auclair and Sagar Lonial and Donna Reece and Paul Richardson and Siegel, {David S.} and Stewart, {Alexander Keith} and Suzanne Trudel and Ravi Vij and Zimmerman, {Todd M.} and Rafael Fonseca",
year = "2017",
doi = "10.1016/j.clml.2017.06.020",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

AU - van Beers, Erik H.

AU - van Vliet, Martin H.

AU - Kuiper, Rowan

AU - de Best, Leonie

AU - Anderson, Kenneth C.

AU - Chari, Ajai

AU - Jagannath, Sundar

AU - Jakubowiak, Andrzej

AU - Kumar, Shaji K

AU - Levy, Joan B.

AU - Auclair, Daniel

AU - Lonial, Sagar

AU - Reece, Donna

AU - Richardson, Paul

AU - Siegel, David S.

AU - Stewart, Alexander Keith

AU - Trudel, Suzanne

AU - Vij, Ravi

AU - Zimmerman, Todd M.

AU - Fonseca, Rafael

PY - 2017

Y1 - 2017

N2 - Background: High risk and low risk multiple myeloma patients follow a very different clinical course as reflected in their PFS and OS. To be clinically useful, methodologies used to identify high and low risk disease must be validated in representative independent clinical data and available so that patients can be managed appropriately. A recent analysis has indicated that SKY92 combined with the International Staging System (ISS) identifies patients with different risk disease with high sensitivity. Patients and Methods: Here we computed the performance of eight gene expression based classifiers SKY92, UAMS70, UAMS80, IFM15, Proliferation Index, Centrosome Index, Cancer Testis Antigen and HM19 as well as the combination of SKY92/ISS in an independent cohort of 91 newly diagnosed MM patients. Results: The classifiers identified between 9%-21% of patients as high risk, with hazard ratios (HRs) between 1.9 and 8.2. Conclusion: Among the eight signatures, SKY92 identified the largest proportion of patients (21%) also with the highest HR (8.2). Our analysis also validated the combination SKY92/ISS for identification of three classes; low risk (42%), intermediate risk (37%) and high risk (21%). Between low risk and high risk classes the HR is >10.

AB - Background: High risk and low risk multiple myeloma patients follow a very different clinical course as reflected in their PFS and OS. To be clinically useful, methodologies used to identify high and low risk disease must be validated in representative independent clinical data and available so that patients can be managed appropriately. A recent analysis has indicated that SKY92 combined with the International Staging System (ISS) identifies patients with different risk disease with high sensitivity. Patients and Methods: Here we computed the performance of eight gene expression based classifiers SKY92, UAMS70, UAMS80, IFM15, Proliferation Index, Centrosome Index, Cancer Testis Antigen and HM19 as well as the combination of SKY92/ISS in an independent cohort of 91 newly diagnosed MM patients. Results: The classifiers identified between 9%-21% of patients as high risk, with hazard ratios (HRs) between 1.9 and 8.2. Conclusion: Among the eight signatures, SKY92 identified the largest proportion of patients (21%) also with the highest HR (8.2). Our analysis also validated the combination SKY92/ISS for identification of three classes; low risk (42%), intermediate risk (37%) and high risk (21%). Between low risk and high risk classes the HR is >10.

KW - Biomarker

KW - Gene expression

KW - In vitro diagnostic clinical assay

KW - Signature

UR - http://www.scopus.com/inward/record.url?scp=85025168323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025168323&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2017.06.020

DO - 10.1016/j.clml.2017.06.020

M3 - Article

C2 - 28735890

AN - SCOPUS:85025168323

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -